Zacks Investment Research Upgrades Ra Pharmctl Inc (RARX) to “Hold”
Ra Pharmctl Inc (NASDAQ:RARX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
A number of other equities analysts have also weighed in on the company. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price objective on shares of Ra Pharmctl in a research note on Friday, July 14th. Royal Bank Of Canada assumed coverage on Ra Pharmctl in a research report on Thursday, September 14th. They issued an “outperform” rating and a $21.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $25.60.
Ra Pharmctl (NASDAQ:RARX) opened at 14.05 on Wednesday. The company’s 50 day moving average price is $14.62 and its 200-day moving average price is $14.62. Ra Pharmctl has a 52 week low of $12.05 and a 52 week high of $24.12. The company’s market capitalization is $317.66 million.
Ra Pharmctl (NASDAQ:RARX) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). Equities research analysts expect that Ra Pharmctl will post ($2.31) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Upgrades Ra Pharmctl Inc (RARX) to “Hold”” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/zacks-investment-research-upgrades-ra-pharmctl-inc-rarx-to-hold-2.html.
A number of institutional investors have recently bought and sold shares of RARX. American International Group Inc. acquired a new stake in Ra Pharmctl during the 1st quarter worth approximately $102,000. TIAA CREF Investment Management LLC raised its stake in shares of Ra Pharmctl by 97.0% during the 1st quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after buying an additional 3,859 shares in the last quarter. Alliancebernstein L.P. purchased a new position in shares of Ra Pharmctl during the 2nd quarter worth approximately $195,000. Wells Fargo & Company MN raised its stake in shares of Ra Pharmctl by 151.8% during the 1st quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock worth $202,000 after buying an additional 5,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Ra Pharmctl by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after buying an additional 2,543 shares in the last quarter. 66.26% of the stock is owned by institutional investors.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.